keyword
MENU ▼
Read by QxMD icon Read
search

primary hypercholesterolemia

keyword
https://www.readbyqxmd.com/read/29121968/association-of-ifitm3-rs12252-polymorphisms-bmi-diabetes-and-hypercholesterolemia-with-mild-flu-in-an-iranian-population
#1
Parvaneh Mehrbod, Sana Eybpoosh, Fatemeh Fotouhi, Hadiseh Shokouhi Targhi, Vahideh Mazaheri, Behrokh Farahmand
BACKGROUND: IFITM3 has been suggested to be associated with infection in some ethnic groups. Diabetes and hypercholesterolemia are also important clinical conditions that can predispose individuals to infection. The aim of this study was to investigate the association of rs12252 C polymorphism, BMI, diabetes, and hypercholesterolemia with mild flu in an Iranian population. METHODS: We conducted a case-control study, including 79 mild flu and 125 flu-negative individuals attending primary care centers of three provinces of Iran (i...
November 9, 2017: Virology Journal
https://www.readbyqxmd.com/read/29110223/the-effectiveness-and-cost-effectiveness-of-plant-sterol-or-stanol-enriched-functional-foods-as-a-primary-prevention-strategy-for-people-with-cardiovascular-disease-risk-in-england-a-modeling-study
#2
Wei Yang, Heather Gage, Daniel Jackson, Monique Raats
This study appraises the effectiveness and cost-effectiveness of consumption of plant sterol-enriched margarine-type spreads for the prevention of cardiovascular disease (CVD) in people with hypercholesterolemia in England, compared to a normal diet. A nested Markov model was employed using the perspective of the British National Health Service (NHS). Effectiveness outcomes were the 10-year CVD risk of individuals with mild (4-6 mmol/l) and high (above 6 mmol/l) cholesterol by gender and age groups (45-54, 55-64, 65-74, 75-85 years); CVD events avoided and QALY gains over 20 years...
November 6, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/29082583/the-risk-of-ischaemic-stroke-in-primary-aps-patients-a-prospective-study
#3
Massimo Radin, Karen Schreiber, Irene Cecchi, Dario Roccatello, Maria José Cuadrado, Savino Sciascia
BACKGROUND: The most common neurological manifestation of APS is ischaemic stroke. Identifying patients with APS at high risk for developing any thrombotic event remains a major challenge. In this study, we aimed to identify predictive factors of ischaemic stroke in a cohort of primary APS (PAPS) patients who presented with new onset symptoms suggestive of acute stroke. METHODS: This prospective multicenter study included 36 consecutive PAPS patients who presented with new onset symptoms suggestive of an acute stroke...
October 30, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29078037/the-effects-of-single-and-multiple-dose-administration-of-bococizumab-rn316-pf-04950615-a-humanized-igg2%C3%AE-a-monoclonal-antibody-binding-proprotein-convertase-subtilisin-kexin-type-9-in-hypercholesterolemic-subjects-treated-with-and-without-atorvastatin-results
#4
Barry Gumbiner, Tenshang Joh, Hong Liang, Hong Wan, Matteo Levisetti, Alicia M Vana, David L Shelton, Philippe Forgues, Stephan Billotte, Jaume Pons, Charles M Baum, Pamela D Garzone
AIMS: Three single-dose and one multiple-dose phase I studies were conducted in subjects with primary hypercholesterolemia to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. METHODS: The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were: 1) ascending, single, intravenous (IV) bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg) or placebo (N=48; baseline low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL); 2) single, IV bococizumab (0...
October 27, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/29075885/long-term-metabolic-effects-of-aripiprazole-ziprasidone-and-quetiapine-a-pragmatic-clinical-trial-in-drug-na%C3%A3-ve-patients-with-a-first-episode-of-non-affective-psychosis
#5
Javier Vázquez-Bourgon, Rocío Pérez-Iglesias, Víctor Ortiz-García de la Foz, Paula Suárez Pinilla, Álvaro Díaz Martínez, Benedicto Crespo-Facorro
INTRODUCTION: The use of second-generation antipsychotics (SGA) has been associated with metabolic changes. However, there are differences in the metabolic profile between SGAs. We have previously observed that ziprasidone had a more benign early metabolic profile compared to aripiprazole and quetiapine. However, a long-term follow-up is preferred to detect clinically relevant impairment in metabolic parameters. We aimed to compare the effect of aripiprazole, ziprasidone, and quetiapine on metabolic measures in first-episode non-affective psychosis patients after 1 year of treatment...
October 26, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29057618/effects-of-12-weeks-of-treatment-with-intravenously-administered-bococizumab-a-humanized-monoclonal-antibody-blocking-proprotein-convertase-subtilisin-kexin-type-9-in-hypercholesterolemic-subjects-on-high-dose-statin
#6
Sergio Fazio, David G Robertson, Tenshang Joh, Hong Wan, Tom Riel, Philippe Forgues, Charles M Baum, Pamela D Garzone, Barry Gumbiner
AIMS: Two multiple-dose phase II studies were conducted in subjects with primary hypercholesterolemia to evaluate the LDL-C lowering efficacy, safety, and tolerability of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. METHODS: The results from the two phase II, double-blinded, randomized, placebo-controlled, multicenter studies conducted in the USA and Canada were combined. In Study 1, 90 subjects with LDL-C ≥100 mg/dL received intravenous (IV) placebo or bococizumab 0...
October 23, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/29031724/elevated-hepatic-dpp4-activity-promotes-insulin-resistance-and-non-alcoholic-fatty-liver-disease
#7
Christian Baumeier, Luisa Schlüter, Sophie Saussenthaler, Thomas Laeger, Maria Rödiger, Stella Amelie Alaze, Louise Fritsche, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche, Robert Wolfgang Schwenk, Annette Schürmann
OBJECTIVE: Increased hepatic expression of dipeptidyl peptidase 4 (DPP4) is associated with non-alcoholic fatty liver disease (NAFLD). Whether this is causative for the development of NAFLD is not yet clarified. Here we investigate the effect of hepatic DPP4 overexpression on the development of liver steatosis in a mouse model of diet-induced obesity. METHODS: Plasma DPP4 activity of subjects with or without NAFLD was analyzed. Wild-type (WT) and liver-specific Dpp4 transgenic mice (Dpp4-Liv-Tg) were fed a high-fat diet and characterized for body weight, body composition, hepatic fat content and insulin sensitivity...
October 2017: Molecular Metabolism
https://www.readbyqxmd.com/read/29028361/new-findings-on-biological-actions-and-clinical-applications-of-royal-jelly-a-review
#8
Mozafar Khazaei, Atefe Ansarian, Elham Ghanbari
Royal jelly (RJ) is a natural bee product with great potential for use in medicine. The chemical composition of RJ indicates the presence of various bioactive substances including 10-hydroxydecanoic acid and 24-methylenecholesterol. In addition, a number of biological and pharmacological activities of RJ have been documented. The aim of this study was to review the biological and medical effects of RJ. The search was conducted in articles from electronic and scientific literature databases such as Pub Med, Science Direct, Scopus, Medline, and ISI Web of Science published from 1990 to 2017 using keywords of pharmacological, biological, and clinical effects and royal jelly...
October 13, 2017: Journal of Dietary Supplements
https://www.readbyqxmd.com/read/29018020/relation-of-low-density-lipoprotein-cholesterol-with-microvascular-injury-and-clinical-outcome-in-revascularized-st-elevation-myocardial-infarction
#9
Martin Reindl, Sebastian Johannes Reinstadler, Hans-Josef Feistritzer, Markus Theurl, Daniel Basic, Christopher Eigler, Magdalena Holzknecht, Johannes Mair, Agnes Mayr, Gert Klug, Bernhard Metzler
BACKGROUND: Microvascular injury (MVI) after primary percutaneous coronary intervention for ST-elevation myocardial infarction (STEMI) is a major determinant of adverse clinical outcome. Experimental data indicate an impact of hypercholesterolemia on MVI; however, there is a lack of clinical studies confirming this relation. We aimed to investigate the association of cholesterol concentrations on admission with MVI visualized by cardiac magnetic resonance imaging and clinical outcome in STEMI patients treated by primary percutaneous coronary intervention...
October 10, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28965797/single-blind-multicentre-randomized-controlled-trial-testing-the-effects-of-a-novel-nutraceutical-compound-on-plasma-lipid-and-cardiovascular-risk-factors-results-of-the-interim-analysis
#10
RANDOMIZED CONTROLLED TRIAL
V Trimarco, A Battistoni, G Tocci, R Coluccia, M V Manzi, R Izzo, M Volpe
BACKGROUND AND AIMS: The clustering of high levels of LDL cholesterol (LDL-C) and other risk factors represents a predisposing condition for atherosclerotic disease development. Cardiovascular prevention is based on effective control of these conditions. In adult subjects with mild hypercholesterolemia we compared in the real life the effects of a new combination of nutraceuticals on lipid and glucose metabolism and blood pressure with those of an established nutraceutical combination...
October 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28965617/detection-of-familial-hypercholesterolemia-in-patients-from-a-general-practice-database
#11
Manuela Casula, Alberico L Catapano, Luigi Rossi Bernardi, Marco Visconti, Alberto Aronica
OBJECTIVES: Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder associated with premature coronary heart disease. Early cholesterol-lowering therapy could effectively reduce cardiovascular disease morbidity and mortality in these patients. However, the majority of people with FH are undiagnosed, also due to low awareness and knowledge of FH in general practice, despite the high number of contacts GPs have with most of their patients which allows a systematic and effective approach to the detection of this condition...
October 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/28965615/familial-hypercholesterolemia-the-italian-atherosclerosis-society-network-lipigen
#12
Maurizio Averna, Angelo B Cefalù, Manuela Casula, Davide Noto, Marcello Arca, Stefano Bertolini, Sebastiano Calandra, Alberico L Catapano, Patrizia Tarugi
BACKGROUND AND AIMS: Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network). METHODS: Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers...
October 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/28952470/-the-efficacy-and-safety-of-pitavastatin
#13
Vedat Sansoy
In short-term, phase III or IV studies in Asian and European patients, pitavastatin 1, 2 and 4 mg once daily reduced LDL-Cholesterol (LDL-C) 34%, 42% and 47%, respectively. Pitavastatin provided sustained LDL-C-lowering efficacy over up to 60 weeks' therapy in extension studies. In comparative studies pitavastatin 4 mg and simvastatin 40 mg reduced LDL-C similarly, reduction in triglycerides and increase in HDL-Cholesterol (HDL-C) was more prominent with pitavastatin. In comparative studies with atorvastatin, pitavastatin 4mg was found to be more effective than 20 mg of atorvastatin, and a little less effective than 40 mg of atorvastatin...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28946037/familial-hypercholesterolemia-in-primary-care-in-germany-diabetes-and-cardiovascular-risk-evaluation-targets-and-essential-data-for-commitment-of-treatment-detect-study
#14
Nina Schmidt, Burkhard Schmidt, Alexander Dressel, Ingrid Gergei, Jens Klotsche, Lars Pieper, Hubert Scharnagl, Marcus E Kleber, Winfried März, Hendrik Lehnert, David Pittrow, Günter Stalla, Hans-Ulrich Wittchen, Tanja B Grammer
BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is an inherited disorder of lipoprotein metabolism characterised by impaired removal of low-density lipoproteins (LDL) from the circulation, which leads to an increased risk of cardiovascular disease (CVD). This risk can be significantly lowered by early diagnosis and treatment. In Germany, reliable estimates of the prevalence of FH are lacking. We therefore examined the prevalence rate of FH in Germany in a primary care based cohort...
November 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28944725/intermediate-risk-of-cardiac-events-and-recurrent-stroke-after-stroke-admission-in-young-adults
#15
Peter Jin, Ivan Matos Diaz, Laura Stein, Alison Thaler, Stanley Tuhrim, Mandip S Dhamoon
Background In older adults with stroke, there is an increased risk of cardiovascular events in the intermediate period, up to one year after stroke. The risk of cardiovascular events in this period in young adults after stroke has not been studied. We hypothesized that in the intermediate risk period, young adults with ischemic stroke have an increased risk of recurrent stroke and a smaller increase of cardiac events. Methods Using the National Readmissions Database during the year 2013, we identified ischemic stroke admissions among those aged 18-45 years using International Classification of Disease, Ninth Revision, Clinical Modification codes to identify index vascular events and risk factors...
January 1, 2017: International Journal of Stroke: Official Journal of the International Stroke Society
https://www.readbyqxmd.com/read/28933629/ezetimibe-ameliorates-steatohepatitis-via-amp-activated-protein-kinase-tfeb-mediated-activation-of-autophagy-and-nlrp3-inflammasome-inhibition
#16
Soo Hyun Kim, Gyuri Kim, Dai Hoon Han, Milim Lee, Irene Kim, Bohkyung Kim, Kook Hwan Kim, Young-Mi Song, Jeong Eun Yoo, Hye Jin Wang, Soo Han Bae, Yong-Ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Myung-Shik Lee
Impairment in macroautophagy/autophagy flux and inflammasome activation are common characteristics of nonalcoholic steatohepatitis (NASH). Considering the lack of approved agents for treating NASH, drugs that can enhance autophagy and modulate inflammasome pathways may be beneficial. Here, we investigated the novel mechanism of ezetimibe, a widely prescribed drug for hypercholesterolemia, as a therapeutic option for ameliorating NASH. Human liver samples with steatosis and NASH were analyzed. For in vitro studies of autophagy and inflammasomes, primary mouse hepatocytes, human hepatoma cells, mouse embryonic fibroblasts with Ampk or Tsc2 knockout, and human or primary mouse macrophages were treated with ezetimibe and palmitate...
October 3, 2017: Autophagy
https://www.readbyqxmd.com/read/28926730/impact-of-evolocumab-treatment-on-low-density-lipoprotein-cholesterol-levels-in-heterozygous-familial-hypercholesterolemic-patients-withdrawing-from-regular-apheresis
#17
Masa-Aki Kawashiri, Atsushi Nohara, Toshinori Higashikata, Hayato Tada, Chiaki Nakanishi, Hirofumi Okada, Tetsuo Konno, Kenji Sakata, Kenshi Hayashi, Akihiro Inazu, Hiroshi Mabuchi, Masakazu Yamagishi
BACKGROUND AND AIMS: Low-density lipoprotein (LDL) apheresis has been used to treat refractory hyperlipidemia such as familial hypercholesterolemia (FH). Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor used in clinical settings, can reduce LDL cholesterol (LDL-C) levels by >70%. Therefore, this study aimed to assess the impact of evolocumab on withdrawal from regular LDL apheresis in patients with heterozygous FH (HeFH). METHODS: Eleven patients with HeFH undergoing biweekly LDL apheresis were enrolled and were subsequently switched to a biweekly subcutaneous injection of 140 mg of evolocumab...
September 9, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28926478/characterization-of-spontaneous-hydrocephalus-development-in-the-young-atherosclerosis-prone-mice
#18
Chuanguo Liu, Guorong Li, Pingping Wang, Yan Wang, Jie Pan
Little has been reported on whether abnormal lipid metabolism affects hydrocephalus, although congenital malformations and infectious diseases are major causal factors for hydrocephalus development. In a study on the pathogenesis of atherogenesis in mice, we unexpectedly discovered that hydrocephalus occurred in partial apolipoptotein E (apoE) and low-density lipoprotein receptor (LDLR) double-knockout (apoE/LDLR) mice fed either chow or a high-fat and high-cholesterol diet between the ages of 4 and 12 weeks...
November 8, 2017: Neuroreport
https://www.readbyqxmd.com/read/28918614/modifiable-co-morbidities-trends-during-hospital-admissions-for-obesity-in-france-2009-2014
#19
Pierre Nanyan
Obesity is a growing public health problem in France, but modifiable co-morbidities in obese patients during their hospital admissions excluding bariatric surgery are lacking. Data were extracted from the French national hospital discharge database. Data on patient admissions, age, gender, and length of stay were extracted by selecting any stay coded primary as obesity. Obesity was defined as body mass index (BMI) between 30-39 kg/m², and morbid obesity as BMI≥40 kg/m². Only modifiable co-morbidities frequently diagnosed during the 6-year period with a rate≥3% were chosen...
July 2017: Acta Medica Iranica
https://www.readbyqxmd.com/read/28918428/modification-of-cardiovascular-pharmacotherapy-in-palliative-care-patients-with-cancer-narrative-review
#20
Tomasz Pasierski
Palliative care cancer patients are treated with many drugs especially at the end of life. Limiting of polypharmacy a decreases the risk of associated adverse effects, medical errors and harmful drug interactions The time lag to benefit of many medications used for cardiovascular diseases or risk factors like hypertension, hypercholesterolemia is frequently longer than palliative care cancer patient's life expectancy. It is ethically appropriate to modify, even to discontinue cardiovascular pharmacotherapy when there is no prospect of benefit...
September 13, 2017: Polish Archives of Internal Medicine
keyword
keyword
65021
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"